Home Ingredients Vinpocetine
Cognitive

Vinpocetine

Evidence Level
Limited
2 Clinical Trials
5 Documented Benefits
2/5 Evidence Score

Vinpocetine is a semi-synthetic derivative of vincamine, an alkaloid from periwinkle (Vinca minor). Discovered in the late 1960s and introduced in Hungary in the 1970s as a prescription drug for cerebrovascular disorders (Cavinton®). Historically prescribed in Eastern Europe and parts of Asia for cerebrovascular disorders; these uses are not recognized by US/Western regulators. Regulatory status: in 2016 FDA tentatively concluded vinpocetine does not qualify as a dietary ingredient and is excluded from the dietary supplement definition because it was first authorized for investigation as a new drug; in 2019 FDA warned women who are or could become pregnant not to take it. Pregnancy absolutely contraindicated.

Studied Dose 5 to 10 mg three times daily (15 to 30 mg/day total); some research uses up to 60 mg/day.
Active Compound Vinpocetine (apovincaminic acid ethyl ester)

Benefits

Prescription Cerebrovascular Use Outside the US (Historical Context)

Developed as a prescription drug (Cavinton) in Hungary and used in parts of Eastern Europe and Asia for cerebrovascular disorders. An independent review of the dementia trials concluded the evidence is inconclusive and does not support clinical use; Western/US regulators have not recognized an outcome benefit, and the FDA has tentatively concluded vinpocetine does not qualify as a dietary supplement. This is not an approved treatment for stroke or any disease.

Supported by Trial 1

Cognitive Support in Older Adults (Inconclusive Evidence)

Older controlled trials in dementia (583 people across three studies) suggested some benefit at 30 and 60 mg/day, but an independent review of the trials concluded the overall evidence is inconclusive and does not support clinical use. Vinpocetine is not established as a treatment for dementia or cognitive decline.

Supported by Trial 1, Trial 2

Tinnitus

A few small older studies reported modest changes in tinnitus, particularly recent-onset cases, but rigorous modern controlled evidence is lacking and this is not an established use. Tinnitus is a medical condition that warrants evaluation by a clinician.

Supported by Trial 2

Cerebral Blood Flow Enhancement

In small studies of IV vinpocetine in stroke patients, one infusion raised a Doppler perfusion signal versus placebo (flow velocity did not differ), and a 2-week PET study found regional shifts in blood flow and glucose metabolism, larger than with a plain infusion (global glucose metabolism did not change markedly). This is a pharmacologic observation, not a demonstrated clinical benefit. Proposed mechanism: PDE1 inhibition.

Supported by Trial 2, Trial 1

Neuroprotection (Mostly Animal Data, Not Established in Humans)

Laboratory and animal studies report neuroprotective effects, with proposed mechanisms including sodium and calcium channel modulation and anti-inflammatory activity. Human data come from drug trials in stroke patients that reviewers judged not yet sufficient for recommendations, so a brain-protective benefit from supplement use has not been established.

Supported by Trial 2, Trial 1

Mechanism of action

1

PDE1 Inhibition (Cerebral Selective)

Inhibits calcium/calmodulin-dependent phosphodiesterase 1 (PDE1); the resulting rise in cGMP in vascular smooth muscle is thought to lower cerebral vascular resistance and raise cerebral blood flow. Early experimental work described this effect as relatively brain-selective, with little change in systemic circulation.

2

Voltage-Dependent Sodium Channel Modulation

Inhibits voltage-dependent sodium channels, which is proposed to protect neurons during ischemia by reducing excitotoxicity. Mechanism shared with some anticonvulsants.

3

Calcium Channel Modulation

Modulates voltage-dependent calcium channels, an additional proposed neuroprotective mechanism.

4

Anti-Platelet Effects

Inhibits platelet aggregation in experimental studies, which may contribute to its effects on blood flow but raises bleeding-risk concerns.

Clinical trials

1
Vinpocetine for Cerebrovascular Disorders (Hungarian and Russian Trials)

Multiple trials of vinpocetine (Cavinton®) in patients with cerebrovascular insufficiency, post-stroke recovery, and vascular cognitive impairment.

Cerebrovascular disease patients.

Individual trials of Cavinton in cerebrovascular disease reported modest changes in cognitive and neurological measures, but the 2003 Cochrane review of the dementia trials judged the overall evidence inconclusive and unsupportive of clinical use. Vinpocetine has prescription status in some Eastern European countries but is not a recognized treatment in Western medicine.

2
Vinpocetine for Tinnitus

Trials of vinpocetine for tinnitus, particularly recent-onset.

Tinnitus patients.

A few small older studies reported modest changes in tinnitus severity and audiometric measures, but rigorous modern controlled evidence is lacking; this is not an established use.

Side effects and drug interactions

Common Potential side effects

FDA warning (2019): animal data link vinpocetine to decreased fetal weight and miscarriage, so women who are pregnant or who could become pregnant should not use vinpocetine. The FDA has also tentatively concluded vinpocetine does not meet the legal definition of a dietary supplement.
Mild GI distress.
Headache.
Sleep disturbance.
Dizziness.
Hypotension (uncommon).
Bleeding risk from antiplatelet effects; a concern around surgery and in bleeding disorders.
Theoretical effects on heart rhythm in those with arrhythmia history.

Important Drug interactions

Anticoagulants (warfarin, DOACs, heparin): additive bleeding risk; avoid without medical supervision.
Antiplatelet drugs (aspirin, clopidogrel, ticagrelor): additive bleeding risk; consult.
Antihypertensives: additive BP effects (modest); monitor.
Anticonvulsants: theoretical interaction via sodium channel effects.
Pre-surgery — discontinue 1-2 weeks before due to bleeding risk.
Pregnancy: FDA warns vinpocetine may cause miscarriage or harm fetal development; absolutely contraindicated.
Lactation — limited safety data; avoid.

More Cognitive Ingredients

Cognitive
Ashwagandha
Ashwagandha (Withania somnifera) is an herb from Ayurvedic tradition whose root extracts a…
Cognitive
KSM-66®
KSM-66 is a widely studied branded ashwagandha (Withania somnifera) extract, made by Ixore…
Cognitive
Phosphatidylcholine
Phosphatidylcholine (PC) is one of the two most abundant phospholipids in cell membranes a…
Cognitive
Phosphatidylserine
Phosphatidylserine (PS) is a phospholipid found in cell membranes and especially abundant…

Explore Other Ingredients

Cognitive
Bacopa Monnieri
Bacopa monnieri, also called brahmi, is an herb used in traditional Ayurvedic practice as…
Cognitive
Lion's Mane Mushroom
Lion's mane (Hericium erinaceus) is an edible medicinal mushroom prized for its potential…
Cognitive
Citicoline
Citicoline (CDP-choline) is a naturally-occurring intermediate in phosphatidylcholine bios…

Frequently asked questions about Vinpocetine

What is vinpocetine?

Vinpocetine is a compound derived from vincamine (from periwinkle), used for cognitive and circulatory support, particularly cerebral blood flow. It is a prescription medicine in some countries; in the US the FDA tentatively concluded in 2016 that it does not meet the legal definition of a dietary supplement, and it is not an approved drug here.

What is vinpocetine used for?

It is studied for supporting blood flow to the brain, memory, and cognitive function, especially related to circulation and age-related concerns. Its proposed mechanism involves widening blood vessels and supporting brain metabolism.

How much vinpocetine is used?

Studies have used about 15 to 30 mg per day, split into doses with meals. Follow product labeling. Note its regulatory status is under review in some places.

Who should avoid vinpocetine?

Pregnant women and those who could become pregnant should avoid it, as the US FDA has warned it may harm fetal development. It may also have mild blood-thinning effects, so check with your doctor if you take anticoagulants or have a medical condition.

What doses of Vinpocetine have been studied?

Vinpocetine is a drug or research chemical, not a dietary supplement: it is a prescription medicine in some countries, is not approved for sale as a supplement in the US, or has a regulatory warning against it. Doses used in studies: 5 to 10 mg three times daily (15 to 30 mg/day total); some research uses up to 60 mg/day. This is not dosing advice.

Is Vinpocetine safe, and does it have side effects?

Vinpocetine is a drug or research chemical, not a dietary supplement: it is a prescription medicine in some countries, is not approved for sale as a supplement in the US, or has a regulatory warning against it. Side effects and cautions reported for Vinpocetine include: FDA warning (2019): animal data link vinpocetine to decreased fetal weight and miscarriage, so women who are pregnant or who could become pregnant should not use vinpocetine. It may also interact with some medications. Vinpocetine is not right for everyone, so check with a healthcare provider first if you are pregnant or breastfeeding, have a medical condition, or take prescription medication.

Does Vinpocetine interact with any medications?

Possible interactions include: Anticoagulants (warfarin, DOACs, heparin): additive bleeding risk; avoid without medical supervision. Antiplatelet drugs (aspirin, clopidogrel, ticagrelor): additive bleeding risk; consult. If you take prescription medication, check with a pharmacist or doctor before using it.

How strong is the scientific evidence for Vinpocetine?

NutraSmarts rates the evidence for Vinpocetine as Limited (2 out of 5). It is backed by 2 study summaries and 10 cited references summarized on this page. A higher rating reflects more, larger, and better-designed human studies. For a drug or research chemical, this rating does not mean it is suitable for self-use.

References(10 citations)

Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.

  1. Szatmari SZ, Whitehouse PJ. Vinpocetine for cognitive impairment and dementia. Cochrane Database Syst Rev. 2003;2003(1):CD003119. doi: 10.1002/14651858.CD003119.PubMedUsed to support: Cochrane systematic review of vinpocetine for cognitive impairment and dementia, which found the human evidence inconclusive. Included honestly, framing the cognitive claims as unproven despite plausible mechanisms.
  2. Bönöczk P, Panczel G, Nagy Z. Vinpocetine increases cerebral blood flow and oxygenation in stroke patients: a near infrared spectroscopy and transcranial Doppler study. Eur J Ultrasound. 2002;15(1-2):85-91. doi: 10.1016/s0929-8266(02)00006-x.PubMedUsed to support: Double-blind, placebo-controlled study of a single 20 mg IV infusion in 43 ischemic stroke patients: versus placebo, deoxyhemoglobin and Doppler spectral intensity rose significantly, while oxy- and total hemoglobin changes did not reach significance. The authors read this as increased perfusion and oxygen extraction.
  3. Szilágyi G, Nagy Z, Balkay L, Boros I, Emri M, Lehel S, Márián T, Molnár T, Szakáll S, Trón L, Bereczki D, Csiba L, Fekete I, Kerényi L, Galuska L, Varga J, Bönöczk P, Vas A, Gulyás B. Effects of vinpocetine on the redistribution of cerebral blood flow and glucose metabolism in chronic ischemic stroke patients: a PET study. J Neurol Sci. 2005;229-230:275-84. doi: 10.1016/j.jns.2004.11.053.PubMedUsed to support: Double-blind PET study in 13 chronic ischemic stroke patients given 14 days of IV infusion with or without vinpocetine: regional blood flow and glucose metabolism shifted in both groups, more so with vinpocetine; global glucose metabolism did not change markedly. Supports the cerebral-circulation mechanism.
  4. Valikovics A. [Investigation of the effect of vinpocetine on cerebral blood flow and cognitive functions]. Ideggyogy Sz. 2007;60(7-8):301-10..PubMedUsed to support: Hungarian-language 12-week pilot study of oral vinpocetine in ischemic stroke and mild cognitive impairment patients, compared only with baseline (no control group): Doppler blood flow measures and cognitive test scores improved. Uncontrolled, so it cannot separate drug effects from other causes.
  5. Farooq MU, Min J, Goshgarian C, Gorelick PB. Pharmacotherapy for Vascular Cognitive Impairment. CNS Drugs. 2017;31(9):759-776. doi: 10.1007/s40263-017-0459-3.PubMedUsed to support: Review of pharmacotherapy for vascular cognitive impairment that situates vinpocetine among options targeting cerebral perfusion. Context for the cognitive use.
  6. Vas A, Gulyás B. Eburnamine derivatives and the brain. Med Res Rev. 2005;25(6):737-57. doi: 10.1002/med.20043.PubMedUsed to support: Review of vinpocetine (an eburnamine derivative) and its brain pharmacology, including phosphodiesterase inhibition and neuroprotection. Supports the mechanism description.
  7. Kiss B, Kárpáti E. [Mechanism of action of vinpocetine]. Acta Pharm Hung. 1996;66(5):213-24..PubMedUsed to support: Hungarian-language review by manufacturer (Gedeon Richter) scientists: Cavinton entered clinical practice in Hungary about twenty years earlier; early experiments showed brain-selective circulatory effects without significant systemic change, PDE inhibition and inhibition of platelet aggregation; neuroprotection in vitro and in vivo linked to sodium channel inhibition.
  8. Jeon KI, Xu X, Aizawa T, Lim JH, Jono H, Kwon DS, Abe J, Berk BC, Li JD, Yan C. Vinpocetine inhibits NF-kappaB-dependent inflammation via an IKK-dependent but PDE-independent mechanism. Proc Natl Acad Sci U S A. 2010;107(21):9795-800..PubMedUsed to support: Laboratory and mouse study: vinpocetine inhibited TNF-alpha-induced NF-kappaB activation and proinflammatory mediators in several cell types and reduced lung inflammation in mice, by targeting IKK. Preclinical support for the anti-inflammatory mechanism only.
  9. Bereczki D, Fekete I. Vinpocetine for acute ischaemic stroke. Cochrane Database Syst Rev. 2008;2008(1):CD000480..PubMedUsed to support: Systematic review of two randomized trials (70 participants) of vinpocetine in acute ischaemic stroke: death or dependency did not differ between vinpocetine and placebo, with wide confidence intervals; the authors found not enough evidence to evaluate its effect.
  10. Panda PK, Ramachandran A, Panda P, Sharawat IK. Safety and Efficacy of Vinpocetine as a Neuroprotective Agent in Acute Ischemic Stroke: A Systematic Review and Meta-Analysis. Neurocrit Care. 2022;37(1):314-325..PubMedUsed to support: Meta-analysis of four placebo-controlled trials of vinpocetine in acute ischemic stroke: fewer patients had death or significant disability at 1 and 3 months, but the authors state more adequately sized double-blind trials are needed before recommending routine use. Context for the unestablished human neuroprotection.